Medical cannabis companies developing pharmaceuticals have largely focused on using purified cannabinoids as monotherapies to treat neurological diseases. This year, for example, Cambridge, U.K.-based GW Pharma plc gained FDA approval for Epidiolex (cannabidiol) to treat two rare pediatric epilepsies, Dravet syndrome and Lennox-Gastaut syndrome, and others are on GW's heels, developing drugs for epilepsy and pain indications. (See BioWorld Insight, Oct. 17, 2016.) Read More
Multiple myeloma (MM) wasn't exactly a headliner at last week's European Society for Medical Oncology (ESMO) 2018 Congress, and maybe that was fortuitous for the space. For the most part, ESMO presentations didn't set the biopharma world on fire. Instead, a number of companies – Adaptimmune Therapeutics plc, Aduro Biotech Inc., Biolinerx Ltd., Clovis Oncology Inc., Deciphera Pharmaceuticals Inc., Idera Pharmaceuticals Inc. and Merck & Co. Inc., among them – were singed by investors on unexciting data, sometimes from others simply in the same class. Read More
